A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- Other: No Intervention
- Registration Number
- NCT06581146
- Lead Sponsor
- Astellas Gene Therapies
- Brief Summary
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 50
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s) or legally authorized representative (LAR(s)) is willing to comply with the recommended schedule of assessments.
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Participants with XLMTM No Intervention Pediatric and adolescent participants with XLMTM.
- Primary Outcome Measures
Name Time Method Incidence rate of cholestasis Up to Week 48 Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.
Point prevalence of cholestasis Day 1 Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).
Prevalence of cholestasis Up to 1 year Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).
- Secondary Outcome Measures
Name Time Method Non-study-specified home healthcare visits Up to Week 48 Frequency and reason for visit will be collected.
Surgeries/procedures Up to Week 48 Frequency and type will be collected.
Genetic variants of MTM1 Up to Week 48 The association between genetic variants of MTM1 and cholestasis will be evaluated.
Risk of cholestasis temporarily associated with environmental modifiers Up to Week 48 Medication use, immunization history, infectious disease history and dietary habits will be collected.
Hospitalizations Up to Week 48 Frequency and reason for hospitalizations will be collected.
Duration of Hospitalizations Up to Week 48 Duration of hospitalization visits will be collected.
Emergency room visits Up to Week 48 Frequency and reason for visit will be collected.
Hepatology specialist visits Up to Week 48 Frequency and reason for visit will be collected.
Scheduled/unscheduled office visits Up to Week 48 Frequency and reason for visit will be collected.
Trial Locations
- Locations (1)
Boston Children's Hospital
🇺🇸Boston, Massachusetts, United States